Gemcitabine and Irinotecan in Treating Patients With Metastatic Kidney Cancer

NeuroTherapia, Inc.

Status and phase

Completed

Phase 2

Conditions

Kidney Cancer

Treatments

Drug: irinotecan hydrochloride

Drug: gemcitabine hydrochloride

Study type

Interventional

Funder types

Other

NIH

Identifiers

NCT00401128

CASE-CCF-6695

P30CA043703 (U.S. NIH Grant/Contract)

Details and patient eligibility

About

RATIONALE: Drugs used in chemotherapy, such as gemcitabine and irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.

PURPOSE: This phase II trial is studying the side effects and how well giving gemcitabine together with irinotecan works in treating patients with metastatic kidney cancer.

Full description

OBJECTIVES:

Determine the response rate in patients with epithelial (clear or nonclear cell) renal cell carcinoma (RCC) treated with gemcitabine hydrochloride and irinotecan hydrochloride.
Compare the response in patients with clear cell RCC vs nonclear cell RCC treated with this regimen.
Determine the toxicities of this regimen.

OUTLINE: This is an open-label study.

Patients receive gemcitabine hydrochloride IV over 30 minutes and irinotecan hydrochloride IV over 90 minutes on days 1 and 8. Treatment repeats every 21 days for at least 6 courses in the absence of unacceptable toxicity or disease progression.

After completion of study treatment, patients are followed every 3 months for 1 year.

PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.

Enrollment

9 patients

Sex

All

Ages

18 to 120 years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

DISEASE CHARACTERISTICS:

Histologically or cytologically confirmed epithelial renal cell carcinoma (RCC), including either clear cell or nonclear cell RCC
Strong clinical evidence or biopsy proof of metastases to a site or sites distant from the primary tumor
Measurable disease
No untreated or progressive CNS metastases

PATIENT CHARACTERISTICS:

ECOG performance status 0-1
Life expectancy > 3 months
Absolute neutrophil count > 1,500/mm³
Platelet count > 100,000/mm³
Hemoglobin > 9.5 g/dL
Creatinine ≤ 1.8 mg/dL
Bilirubin < 1.5 mg/dL
Calcium < 11.5 mg/dL
ALT and AST < 3 times upper limit of normal
No history of any of the following:
- Serious cardiac arrhythmia or cardiac arrhythmia requiring treatment
- Congestive heart failure
- Angina pectoris
- Other severe cardiovascular disease producing limitations of physical activity (i.e., New York Heart Association class III-IV heart disease)
No other prior malignancy except for the following:
- Basal cell or squamous cell carcinoma of the skin
- Carcinoma in situ of the uterine cervix
- Any malignancy treated with curative intent and in complete remission for > 3 years
No active peptic ulcer disease, inflammatory bowel disease, or chronic diarrhea
No local or systemic infections requiring IV antibiotics within the past 28 days
Not pregnant or nursing
Negative pregnancy test
Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

Recovered from prior hormonal therapy, radiotherapy, biologic therapy, or chemotherapy
No more than 3 prior therapeutic regimens for metastatic disease
No prior organ allograft
More than 28 days since prior major surgery requiring general anesthesia
More than 28 days since prior radiotherapy to control pain from skeletal lesions
More than 28 days since prior hormonal treatment